Evidence map›Paper›PMID 36463172›Full record

ArticleBMC public health2022

Assessing barriers to access and equity for COVID-19 vaccination in the US.

Michael Kuehn, Joyce LaMori, Jessica K DeMartino, Marco Mesa-Frias, Jason Doran, Lohit Korrapati, Rhea Bhojwani, Patrick Lefebvre, Noam Kirson

Abstract read
In one paragraph

Article in BMC public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. "It's not about me. It's about what's best for my community": Factors impacting COVID-19 vaccine uptake among Native Americans and Latinos from two agricultural communities.The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association · 2025
    Article
  11. Article
  12. "Black Is Not Monolithic": Complexities in COVID-19 Vaccine Decision-Making.Journal of racial and ethnic health disparities · 2025
    Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Michael KuehnAnalysis Group, Inc., 151 W 42nd Street, 23rd floor, New York, NY, USA. michael.kuehn@analysisgroup.com.
Joyce LaMoriJanssen Scientific Affairs, LLC, Titusville, NJ, USA.
Jessica K DeMartinoJanssen Scientific Affairs, LLC, Titusville, NJ, USA.
Marco Mesa-FriasJanssen Scientific Affairs, LLC, Titusville, NJ, USA.
Jason DoranAnalysis Group, Inc., Menlo Park, CA, USA.
Lohit KorrapatiAnalysis Group, Inc., San Francisco, CA, USA.
Rhea BhojwaniAnalysis Group, Inc., Menlo Park, CA, USA.
Patrick LefebvreGroupe d'analyseLtée, Montréal, QC, Canada.
Noam KirsonAnalysis Group, Inc., Boston, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHistorical vaccination coverage in economically disadvantaged, ethnic minority, non-affluent white and agricultural populations in the US has lagged coverage in more affluent urban and suburban white populations due to a variety of social and economic factors. In the current COVID-19 pandemic, sociocultural and economic challenges continue to present significant obstacles to achieving equitable uptake of COVID-19 vaccines. The goal of this study was to qualitatively assess perceptions of key US healthcare stakeholders of the most significant barriers to COVID-19 vaccine access and equity to better characterize their expected impact on US communities.

methodsAfter conducting a targeted literature review (TLR), we hypothesized 20 high-impact barriers which included structural and logistical barriers, capturing systemic challenges to vaccine accessibility, and attitudinal and informational barriers, affecting patient willingness to pursue vaccination. We developed a qualitative discussion guide, which included both open-ended and closed-ended questions, and interview stimulus material to conduct one-on-one in-depth interviews to assess the expected prevalence, severity, and persistence of these 20 high-impact barriers, which were hypothesized based on TLR. As a part of this qualitative study, we conducted one-on-one in-depth interviews with a diverse set of 15 US healthcare stakeholders who were involved in the COVID-19 vaccine rollout in states with relatively disparate vaccination rates by ethnicity. These stakeholders were selected to reflect an array of roles in the COVID-19 vaccine rollout, including infectious disease specialists, pharmacists, community advocacy representatives, and partners of local governments involved in the COVID-19 vaccine rollout and community education.

resultsRespondents identified limited vaccination sites in rural settings and technology-related barriers as the most prevalent and severe structural and logistical barriers in US communities. Respondents assessed COVID-19 vaccine safety concerns and politically motivated skepticism to be the most prevalent and severe attitudinal and informational barriers. Respondents cited proliferation of mobile vaccination clinics and local community messaging to endorse vaccines as the most effective solutions to these top structural and attitudinal barriers. Respondents expected politically motivated skepticism to be the most significant and persistent barrier to broader vaccine uptake in the US.

conclusionsOur study suggests that attitudinal barriers, particularly politically motivated skepticism, are likely to remain the most persistent challenges to widespread vaccination against COVID-19 in the US.

Indexed as

COVID-19COVID-19 VaccinesEthnicityHumansMinority GroupsPandemicsVaccinationCOVID-19 VaccinesCommunity HealthHealth DisparitiesHealth EquityPopulation HealthPreventive Medicine

Identifiers

PMID36463172
PMCPMC9719622

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.